Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

B. Wake, C. Hyde, S. Bryan, P. M. Barton, F. Song, A. Fry-Smith, C. Davenport

Research output: Contribution to journalArticle

22 Citations (Scopus)
Original languageEnglish
Pages (from-to)1-85
Number of pages85
JournalHealth Technology Assessment
Issue number3
Publication statusPublished - 2002

Cite this